News

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
After rising roughly 14% in Monday's trading, Newsmax stock is continuing to move higher in today's session. The stock is seeing some significant recovery after big sell-offs last week, but the gains ...
While Apple is getting a big break, the relief may be short lived. President Trump later clarified that electronics like Apple's iPhones would be moving into a different tariff "bucket." While Apple's ...
Applying for Social Security is an exciting milestone for many seniors. Yes, there's paperwork involved, but you're just one ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's ...
With 903 locations worldwide (623 in the U.S. and Puerto Rico) and a recent market value of $428 billion, it may be hard for Costco to grow at a rapid clip. Also, if a widely feared recession happens, ...
Quantum computing could be the next frontier for computers and cloud-based services. While traditional computers still store data in binary bits of zeros and ones, quantum compute ...
1 Wall Street Analyst Says There's a Great Investment Hiding in Plain Sight. These 2 Dividend Stocks Are My Best Ideas for Investing in It.
In today's video, I discuss Nvidia ( NVDA 0.99%), Apple ( AAPL -0.26%), and recent updates about tariffs. To learn more, check out the short video, consider subscribing, and click the special offer ...
Goldman Sachs ( GS 1.95%), a leading global investment banking firm, revealed its Q1 2025 GAAP earnings on 2025-04-14. The Q1 ...
In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia Cavazzoni, M.D., stepped down in January and joined Pfizer's C-suite as chief ...